-transparent.png){kind=logo}
The effect of cholestyramine (4 g t.i.d. for 5 days) on the steady-state plasma concentrations of imipramine and desipramine was assessed in six depressed patients receiving chronic treatment with imipramine (75-150 mg/day). Compared with baseline, cholestyramine treatment was associated with an average 23% decrease in plasma imipramine levels [from 211 +/- 95 to 159 +/- 67 nmol/L, (mean +/- SD), p < 0.05], whereas desipramine levels decreased only marginally. These data suggest that administration of cholestyramine at therapeutic doses impairs the gastrointestinal absorption of concurrently prescribed imipramine by an extent that is potentially clinically significant.
Related Publications
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
August 1990,
Journal of clinical psychopharmacology,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
June 1987,
Therapeutic drug monitoring,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
February 1988,
The Journal of clinical psychiatry,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
April 1982,
Journal of clinical psychopharmacology,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
June 1986,
Journal of clinical psychopharmacology,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
April 1989,
Biological psychiatry,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
February 1988,
Biological psychiatry,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
January 1980,
Communications in psychopharmacology,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
January 1980,
Progress in neuro-psychopharmacology,
E Spina, and
A Avenoso, and
G M Campo, and
A P Caputi, and
E Perucca
July 1980,
Science (New York, N.Y.),
